PMID: 11905751Mar 22, 2002Paper

The use of dendritic cells in cancer therapy

The Lancet Oncology
Michael JeffordIan D Davis

Abstract

Although the immune system evolved to protect the host from infection, what fires the popular imagination is its potential to recognise and destroy cancer. The immune system can generate potent cytotoxicity (eg transplant rejection), but can these mechanisms be harnessed for therapeutic benefit in patients with cancer? The discovery of an ever-increasing array of tumour antigens shows clearly that the targets exist. The challenge lies in generating a sufficiently potent response towards them. Central to the processes of antigen recognition, processing, and presentation to the immune system are dendritic cells. Understanding of the relation between these and the cellular immune response is crucial to elucidation of how to manipulate immune responses. The past 20 years have witnessed a dramatic expansion in this understanding and led to the first early-phase clinical trials of dendritic cells for the treatment of cancer. These studies have established the safety and feasibility of this approach and have produced encouraging evidence of therapeutic efficacy. This paper reviews the biology of dendritic cells and their use in clinical trials, as well as highlighting issues for future trial design.

References

Apr 1, 1990·The Journal of Experimental Medicine·J W Young, R M Steinman
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A KnuthK H Meyer zum Büschenfelde
May 1, 1995·European Journal of Immunology·A Mehta-DamaniE G Engleman
Jul 1, 1994·The Journal of Experimental Medicine·N RomaniG Schuler
Jan 1, 1994·Annual Review of Immunology·P Matzinger
Dec 11, 1995·International Journal of Cancer. Journal International Du Cancer·M MarchandY Humblet
Aug 14, 1997·Nature·I Hart, C Colaco
Jan 7, 1998·Critical Reviews in Immunology·A ChoudhuryD F Claxton
Apr 1, 1998·Nature·J Banchereau, R M Steinman
Sep 28, 1998·The New England Journal of Medicine·W M Stadler, N J Vogelzang
Oct 9, 1998·American Journal of Reproductive Immunology : AJRI·D Fiszer, M Kurpisz
Oct 31, 1998·Current Opinion in Immunology·D M Pardoll, S L Topalian
Jan 1, 1997·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·G L DeNardoS J DeNardo
Dec 8, 1998·The Journal of Experimental Medicine·B PulendranC R Maliszewski
Jul 1, 1999·The Prostate·B A TjoaG P Murphy
Jul 20, 1999·The Journal of Clinical Investigation·M V DhodapkarN Bhardwaj
Jan 25, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L ZitvogelS Amigorena
Mar 23, 2000·The Journal of Clinical Investigation·M V DhodapkarN Bhardwaj
Apr 13, 2000·International Journal of Cancer. Journal International Du Cancer·A MackensenA Lindemann
Aug 19, 2000·Cancer Chemotherapy and Pharmacology·M B Nielsen, F M Marincola

❮ Previous
Next ❯

Citations

Sep 11, 2007·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Hongju LiuQiong Zhou
Oct 27, 2004·Blood Reviews·Volker L ReichardtLothar Kanz
Dec 31, 2003·Trends in Immunology·Megan A CooperMichael A Caligiuri
Dec 14, 2002·Human Immunology·Bianca BlomHergen Spits
Feb 12, 2010·Nature Reviews. Cancer·Gail P RisbridgerWayne D Tilley
Apr 11, 2007·Prostate Cancer and Prostatic Diseases·E Elkord
Feb 18, 2003·Journal of Internal Medicine·P Nygren, R Larsson
Feb 21, 2004·American Journal of Respiratory Cell and Molecular Biology·Martin P BardBart N Lambrecht
Jul 20, 2010·Immunotherapy·Telma Miyuki OshiroAlberto José da Silva Duarte
Dec 23, 2010·Immunotherapy·Yasuhiko NishiokaSaburo Sone
Jun 2, 2011·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Ana DragicevićMiodrag Colić
Mar 21, 2002·The Lancet Oncology·Paul D Nathan, Tim G Eisen
Dec 8, 2004·The Lancet Oncology·Simone MocellinCarlo Riccardo Rossi
Oct 29, 2013·Pathology Oncology Research : POR·János HunyadiEva Rajnavölgyi
Feb 5, 2005·Cancer Immunology, Immunotherapy : CII·Steven De VleeschouwerStefaan W Van Gool
Feb 14, 2012·Journal of Cancer Research and Clinical Oncology·Jian GaoTao Deng
Sep 4, 2003·Leukemia & Lymphoma·Françoise Vuillier, Guillaume Dighiero
Apr 16, 2003·European Journal of Haematology·Régis T CostelloD Olive
Sep 12, 2009·Brain Pathology·Stefaan Van GoolSteven De Vleeschouwer
Nov 11, 2008·Oral Diseases·E HannaS K Libutti
Aug 6, 2003·Expert Review of Vaccines·François Villinger
Sep 8, 2004·Experimental Cell Research·Simone MocellinDonato Nitti
Jun 5, 2007·Expert Review of Vaccines·Hua ZhongBaohui Han
Apr 22, 2003·Pathology Oncology Research : POR·József TímárLászló Kopper
Apr 10, 2010·International Journal of Immunopathology and Pharmacology·J VanderlochtW T V Germeraad
Aug 21, 2021·Scientific Reports·Katarzyna MilowskaMaria Bryszewska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Journal of Controlled Release : Official Journal of the Controlled Release Society
Wiebke FischerRainer Haag
Immunotherapy
Anna-Katharina Thomas-Kaskel, Hendrik Veelken
© 2022 Meta ULC. All rights reserved